Diabetes management is on the verge of being disrupted by innovative technologies such as artificial pancreas, non-invasive glucose monitoring sensors, wearables, apps, and inhalable insulin. This research study captures all the innovative developments across the segments of wellness, diagnosis, monitoring, and therapy of the diabetes care continuum, covering the global market.

Diabetes remains one of the top causes of mortality, and health expenditure on the disorder and its complications is set to rise 19% annually until 2040, to reach $802 billion.

•     Beyond the traditional focus and high-interest areas of monitoring and therapy, rising diabetes prevalence and costs are resulting in the focus gradually shifting to preventing diabetes, and on the overall wellbeing of diabetics and pre-diabetics, resulting in the highest double-digit growth of the wellness segment.
•     Diagnosis, however, remains a neglected aspect of diabetes and novel approaches may be necessary to improve screening and diagnosing patients earlier to save on long-term costs.
•     Monitoring developments that help improve the quality of life of diabetics include blood glucose monitoring tech advances (traditional glucometers and also semi-invasive, implants, and non-invasive continuous glucose monitoring systems), data analytics support, care delivery support, and overall diabetes management support in the form of apps, telehealth, and insulin dosing calculation support.
•     Therapy, the largest segment, is also seeing several improvements in terms of better drugs, combination drugs, better insulin forms, and better delivery mechanisms. Of course, the main development in this segment is that of artificial pancreas—there is one commercially available system and several being developed with varying approaches and features. The other notable “permanent cure” approach is cell therapy involving regenerative medicine techniques with variations in the approaches for transplantation.

The study provides an exhaustive coverage of the overall diabetes ecosystem, with strong focus on startups, apart from the existing stakeholders. It also analyzes the role that technology giants such as Alphabet (née Google) and IBM are playing in the diabetes space. An overview of several innovative diabetes care delivery models from across the world is also included. The study would be valuable for diabetes stakeholders to chart out their strategies for future collaborations and partnerships, while keeping a watchful eye on the competition.

Key questions this study will answer:
•     How is the diabetes burden evolving across the globe?
•     How are market forces and trends shaping the diabetes market and the segments of wellness, diagnosis, monitoring, and therapy?
•     What gaps in diabetic care need to be filled to address the unmet needs of diabetics?
•     What are the technological developments in the industry that attempt to address such unmet needs?
•     How have some care models perfected diabetes management, catering to local needs? What are some future perspectives for the industry?